GSK Stock Down 14% in Six Months: Time to Buy, Hold or Exit?

Summary

GSK stock has declined 14% over the past six months, prompting analysis of whether investors should buy, hold, or sell the position. No specific clinical, regulatory, or financial catalysts are mentioned in this article.